Greenlight Guru connects design, risk, and quality records—but traceability is not a device-release decision

Traceability makes the release argument inspectable

Greenlight Guru's current product page positions quality management for medical-device organizations alongside product development, design controls, risk, and product traceability. It also describes connected document, training, supplier, event, CAPA, complaint, audit, and review workflows. That combination can help a team follow a requirement into design outputs, verification or validation evidence, risk controls, changes, and the quality records that affect a product baseline.

The chain is valuable because release reviewers need to understand more than whether documents exist. They need to know which approved requirement and product version each result supports, whether the test used the intended method and configuration, whether failures and deviations were resolved, and whether residual risks and open quality events were considered. A complete-looking trace matrix can still point to stale, superseded, failed, out-of-scope, or unapproved evidence.

Keep evidence state separate from release authority

A governed release package should retain the device or product family, intended use, design baseline, requirement version, risk-control linkage, verification and validation protocol and result, software and hardware configuration, manufacturing or supplier evidence, applicable change orders, deviations, nonconformances, CAPAs, complaint or post-market signals where relevant, reviewer qualifications, signatures, and effective dates. Every link should show whether the underlying record is draft, approved, executed, passed, failed, superseded, reopened, or conditionally accepted.

Release should remain its own decision object with defined criteria, required evidence, unresolved exceptions, accountable reviewers, electronic approval, time, scope, and any conditions. The platform can surface missing relationships and route work, but it should not infer approval merely because each expected row has an attachment. When a requirement, test method, risk control, component, supplier, manufacturing process, or software version changes, the system should identify affected conclusions and preserve the earlier release record rather than silently repainting history.

Challenge the chain with a late design change

A representative evaluation should begin with an approved design baseline and linked test evidence, then revise one safety-related requirement after a failed verification, update the risk control, change a supplied component, and leave one training or process record incomplete. Reviewers should see which evidence becomes stale, which tests remain reusable, which quality records block or condition release, who can approve an exception, and whether the final decision can be reconstructed without relying on today's overwritten state.

Greenlight Guru's official page supports the described medical-device quality, design-control, risk, traceability, and workflow positioning, but no configured requirement, trace matrix, risk file, protocol, quality event, CAPA, supplier record, release workflow, validation package, implementation, or customer outcome was independently tested here. Quality, regulatory, engineering, clinical, manufacturing, supplier, software, and release authorities must define and approve the product-specific decision. Connected evidence supports review; it does not establish conformity, safety, effectiveness, validated status, or release.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.